Amgen reported $38.1B of revenue over the trailing twelve months, +9.1% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $38.1B (to Q2 2026). Net income: $8.74B, trailing twelve months to Q2 2026. Free cash flow: $10.2B, trailing twelve months to Q2 2026. Operating margin: 30%, trailing twelve months to Q2 2026.

AMGNAmgen

Healthcare

$414.93+54% 1Y

$414.93

$265.4052 weeks$444.20

AMGN as reported

Amgen reported $38.1B of revenue over the trailing twelve months, +9.1% on the year before. 11 reported series are charted on this page, each one as filed.

$38.1B

Revenue, trailing twelve months · to Q2 2026 · +9.1% against the twelve months before

Net income: $8.74B
Net income · +32% year on year · trailing twelve months to Q2 2026
Free cash flow: $10.2B
Free cash flow · −4.1% year on year · trailing twelve months to Q2 2026
Operating margin: 30%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for AMGN, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$38.1B	+9.1%	Q2 2026
Net income	$8.74B	+32%	Q2 2026
EPS	$16.10	+32%	Q2 2026
Gross margin	69%	n/a	Q2 2026
Operating margin	30%	n/a	Q2 2026
Net margin	23%	n/a	Q2 2026
ROE	80%	n/a	Q2 2026
ROA	8.5%	n/a	Q2 2026
ROIC	14%	n/a	Q2 2026
Free cash flow	$10.2B	−4.1%	Q2 2026
P/E	25.8	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.